President Donald Trump announced Tuesday that generic drugs imported into the United States will face a zero tariff through August 2026, before a phased escalation imposes a 100% levy in August 2028 and a 200% rate the following year.

The announcement, made in a post on Truth Social, frames the tariff schedule explicitly as punitive for companies that choose not to act.¹ "This is done in order to reshore generic pharmaceutical production into America, with a penalty to those companies that decide not to build plant and equipment within the stated period of time given to them," Trump wrote. The policy applies to generic drugs only; tariffs on patented, branded and innovative medicines, Trump said, "will remain as is."¹

Who’s most at risk?

According to a report from CNBC, the stakes are expected to be raised for India, whose pharmaceutical companies supply nearly 50% of all generic medicines consumed in the U.S., accounting for roughly one-third of India's pharma exports annually.² China, meanwhile, dominates the upstream supply of active pharmaceutical ingredients, including compounds like amoxicillin and heparin, meaning the actual supply chain exposure extends well beyond the countries that assemble and ship finished products.²

Arpit Chaturvedi, South Asia advisor at Teneo, called the announcement a substantial long-term risk for Indian drugmakers even given the two-year reprieve. "The pharmaceutical sector is among the country's largest net export earners, and full implementation of Trump's stated tariffs would deal a serious blow to India's trade balance," Chaturvedi said. Adding that the two-year runway offers New Delhi a critical negotiating window to push for tariff relief in ongoing U.S.-India trade talks, potentially through corporate investment commitments in America.²

Chaturvedi also flagged a structural market risk: with margins on many generic drugs already thin, some manufacturers may exit specific products entirely if wholesalers refuse to absorb the added cost, rendering those products commercially unviable.

Will tariffs actually move manufacturing?

Deborah Elms, head of trade policy at the Hinrich Foundation, noted that building pharmaceutical manufacturing in the U.S. is both complex and expensive, noting that nearly all inputs would still need to be imported regardless. "I am not sure that even a potential 200% tariff will change the fundamental math," Elms said.

The administration's position, however, is that the direction of travel is already shifting, as Trump's Truth Social post pointed to a wave of domestic facility investment as evidence the policy is working: "Pharmaceutical facilities are being built, at a level never seen before, all over the United States of America."

What is the broader tariff context?

The generic drug announcement extends a pharmaceutical tariff framework Trump has been building throughout his second term. Back on April 2, the administration imposed a 100% levy on patented pharmaceutical products and their ingredients under Section 232, exempting generics, biosimilars and related ingredients at that time. Larger drugmakers were given 120 days before the 100% rate would take effect while smaller manufacturers reliant on contract producers had 180 days.

More than a dozen major companies, including Eli Lilly, Novo Nordisk, and Pfizer have struck separate pricing deals under the administration's most-favored-nation policy, which ties U.S. drug prices to cheaper rates abroad and exempts participating companies from tariffs for three years.

What happens next?

With the stated tariffs not taking effect until 2028, which is an election year, Chaturvedi suggested Indian policymakers may be counting on political recalibration before the levies actually bite. "New Delhi would hope that this rule will not be implemented," he said. In the meantime, he expects Indian generic manufacturers to pursue a multi-pronged response: lobbying Washington for exemptions, accelerating FDA approval filings, pursuing U.S. contract manufacturing agreements and diversifying their export footprints into new markets.²

Sources

1. President Trump Truth Social Account Truth Social July 21, 2026 https://truthsocial.com/@realDonaldTrump/posts/116960425128744506
2. Trump plans generic drug tariffs from 2028 with two-year delay testing U.S. onshoring push CNBC July 21, 2026 https://www.cnbc.com/2026/07/22/trump-generic-drugs-tariffs-medicine-trade-.html